CClinicalTrials.gg
CompletedNCT06211010Updated Jan 18, 2024

The Target Urine VOCs Biosensor for Genitourinary Malignancy Detection

An observational study in The Phenomenon of the Decrease in the Electrical Resistance Within the Conducting Chambers, Making the Increase in a Conducting Property, sponsored by Suranaree University of Technology. Completed at 1 site in Thailand. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-18.

Sponsored by Suranaree University of Technology · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
64
Ages
16 Years and older
Sex
All
01

Study summary

Volatile organic compounds (VOCs) have grown due to their crucial role in transitioning from invasive to noninvasive cancer diagnostic methods. This study aimed to assess the feasibility of the metal oxide biosensor platform using urine VOCs for detecting genitourinary cancers.

Five different commercially available semiconductor sensors were chosen to detect specific VOCs (methane, iso-butane, hydrogen, ethanol, hydrogen sulfide, ammonia, toluene, butane, propane, trimethylamine, and methyl-mercaptan). Changes in electrical resistance due to temperature variations from the voltage heater were examined to characterize VOC metabolism. Logistic regression and ROC analysis were employed to evaluate potential urine VOCs for genitourinary cancer determination.

Read the detailed description

Nowadays, the development of semiconductor metal oxide sensors allows the detection of VOCs from breath and urine by relying on the change of voltage and electrical resistance. The studies use electric current to evaporate VOCs and focus on the changes of evaporation at different temperatures. The results from the previous studies have shown that the changes in the voltage and electrical current resistance dynamics in the semiconductor metal oxide sensors indicate specific patterns that are specific to different types of VOCs. Therefore, this could transit the odor-fingerprint in biogas expression platform to the electrical expression platform due to the possibility of specific-disease VOC identification and the cost-effectiveness of the electrical expression platform when compared to SPME and GC-MS.

This is a descriptive cohort study conducted among 64 subjects attending outpatient clinic at during August 2021 to July 2023. All the subjects were advised and voluntarily signed a consent form before participating in our study. The patients with the renal diseases and the normal subjects were prohibited to have strong odor food (such as tea, coffee, onion, garlic, shrimp paste, acacia, fermented fish, pakria, and celery, etc.) for at least 3 hours before the examination of urine VOCs and were prohibited alcohol intakes for more than 24 hours prior to the urine VOCs examination. The urine samples were collected for 20 mL in universal bottles and samples were classified as genitourinary (kidney/bladder/prostate) cancer or non-cancer or normal control after pathological examination of the biopsy specimens. The urine samples were kept at room temperature and taken to be analyzed with the semiconductor sensors within 30 minutes after the samples were collected.

We selected five different commercially available semiconductor metal oxide sensors to detect all the targeted VOCs, which are methane, iso-butane, hydrogen, ethanol, hydrogen sulfide, ammonia, toluene, butane, propane, trimethylamine, methyl-mercaptan (manufactured by Figaro company). These are the types of VOCs which had been studied and were shown to be related to the malignant according to the literature. The detailed products and basic semiconductor circuits are available in the Figaro Product Information Manual (https://www.figarosensor.com/product/sensor/).

02

Conditions studied

  • The Phenomenon of the Decrease in the Electrical Resistance Within the Conducting Chambers, Making the Increase in a Conducting Property

Keywords

  • Volatile Organic Compounds (VOCs)
  • Biosensor
  • Genitourinary Cancer
03

In context

Lead sponsor

Suranaree University of Technology is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

pateints at Nephrology and Urology clinic of Suranaree University of Technology

Inclusion criteria

  • Age > 16 years

Exclusion criteria

Exclusion Criteria:

  • The patients with the renal diseases and the normal subjects were prohibited to have strong odor food
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
64 participants (actual)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Interventions

  • Diagnostic testthe semiconductor metal oxide sensors.

    The method of analyzing the VOCs was through analyzing the evaporated VOCs from the urine in the container when they evaporated into the sealed chamber. The VOCs in the chamber were then analyzed at the same time by the five different gas semiconductor sensors which were located on the top of the chamber.

    Also known as: The detailed products and basic semiconductor circuits are available in the Figaro Product Information Manual (https://www.figarosensor.com/product/sensor/).

06

What researchers measure

Primary outcomes

  1. the Target Urine Volatile Organic Compounds from urinary cancers

    urine VOCs for detecting genitourinary cancers

    Time frame: DEC 2021-SEP 2023

07

Study locations

1 site
  • Institute of Medicine, Suranaree University of Technology
    Nakhon Ratchasima, 30000, Thailand
08

References and documents

Individual participant data

Plan to share: No — pateints' name and hospital numbers were not indebtifed.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06211010
Lead sponsor
Suranaree University of Technology
Responsible party
CHATCHAI (Associate Professor Dr. Chatchai Kreepala, M.D., Suranaree University of Technology) — Principal investigator
First posted
Jan 18, 2024
Start date
Dec 1, 2021
Primary completion
Sep 1, 2023
Completion
Nov 1, 2023
Last update
Jan 18, 2024

Study contacts

Chatchai Kreepala, M.D.
principal investigator · School of Internal Medicine, Institute of Medicine, Suranaree University of Technology, Thailand

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion